Carolina Molecular Becomes First U.S. Provider of Pixelgen Proxiome Kit for Protein Interactomics

Carolina Molecular Partners with Pixelgen Technologies

Carolina Molecular Inc., a premier molecular testing lab, has made significant strides in the life sciences by announcing its partnership with Pixelgen Technologies AB. This collaboration positions Carolina Molecular as the first certified service provider of Pixelgen's advanced Proxiome Kit in the United States, paving the way for enhanced research capabilities in protein interactomics.

What is the Proxiome Kit?

The Proxiome Kit is an innovative product designed to provide novel insights into the complexities of protein-protein interactions within immune cells. At its core, this technology enables researchers to analyze the spatial relationship between proteins on the cell surface, a crucial factor in various fields such as immuno-oncology and cell therapy. By measuring how closely proteins interact, researchers can gain a deeper understanding of cellular functions and mechanisms, vital for advancing their studies.

Key Features of the Proxiome Kit

One of the standout features of the Proxiome Kit is its ability to deliver cutting-edge 3D protein interactomics. The kit utilizes DNA-barcoded antibodies and rolling circle amplification to create high-resolution maps of protein colocalization, clustering, and abundance. These maps provide unprecedented insights into disease mechanisms, drug responses, and biomarker discovery. Moreover, the kit generates sequencer-ready libraries, ensuring seamless integration with standard next-generation sequencing (NGS) platforms.

A Strategic Collaboration

Trent Carrier, President of Carolina Molecular, emphasized the importance of this partnership by stating, “Our clients are increasingly seeking molecular insights that are supported by complex multiomic studies. As the first U.S. service provider for Pixelgen, we can deliver a powerful tool to our partners that aids in dissecting critical protein-protein interactions, accelerating their therapeutic programs.”

This collaboration comes at a crucial time as U.S. researchers express a growing need for reliable domestic service providers capable of managing sensitive samples and delivering expedited results. Carolina Molecular intends to leverage its established expertise in sequencing and bioinformatics to provide robust, high-quality data to its clientele utilizing the Pixelgen platform.

Industry Impact

Simon Fredriksson, co-founder and CEO of Pixelgen, articulated the significance of the partnership, stating that establishing a robust service provider network is key to making protein interactomics accessible to a wider scientific audience. “Our collaboration with Carolina Molecular represents a leap forward in providing the necessary data to understand complex biological systems, particularly in critical fields like cell therapy and immuno-oncology,” he commented.

About Carolina Molecular

Established over 25 years ago, Carolina Molecular is recognized for its exceptional service in molecular testing, offering CAP/CLIA-certified and NYS-registered testing services targeting CROs and clinical trial sponsors. Their NGS Foundry supports rapid sequencing projects, while their Quality Control offerings cater to biomanufacturing, food safety, and environmental monitoring. Carolina Molecular is dedicated to simplifying the molecular testing process, ensuring high-quality standards, and delivering unparalleled customer service.

About Pixelgen Technologies

Founded in 2020, Pixelgen Technologies AB aims to unveil the molecular foundations of cellular functions through cutting-edge technology. The company is committed to enhancing precision medicine via its Proximity Network Assay, which empowers researchers with nanoscale spatial analysis of immune cell proteins. Pixelgen is not only dedicated to advancing scientific understanding but also to developing a robust portfolio of products for translational research.

This partnership marks a pivotal moment in the intersection of molecular testing and advanced protein interactomics, promising to empower researchers and ultimately expedite the discovery of therapies that can change lives.